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license (http://creative(AD). Kallikrein-8 is a protease implicated in memory acquisition and anxiety, and its mRNA is
known to be up-regulated in AD-affected human hippocampus. Therefore, an involvement of
Kallikrein-8 in Alzheimer’s pathogenesis is conceivable but remains to be proved.
Methods: We determined the cerebral expression of Kallikrein-8 mRNA and protein during the
course of AD in patients and in transgenic mice and tested the impact of Kallikrein-8 inhibition on
AD-related pathology in mice and in primary glial cells.
Results: Kallikrein-8 mRNA and protein were up-regulated in both species at incipient stages of AD.
Kallikrein-8 inhibition impeded amyloidogenic amyloid-precursor-protein processing, facilitated
amyloid b (Ab) clearance across the blood-brain-barrier, boosted autophagy, reduced Ab load and
tau pathology, enhanced neuroplasticity, reversed molecular signatures of anxiety, and ultimately
improved memory and reduced fear.
Discussion: Kallikrein-8 is a promising new therapeutic target against AD.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; Kallikrein-8; Intraventricular antibody delivery; Ephrin receptor B2; Anxiety; Neuroplastic-ity; Ab pathology; Ab clearance; Autophagy; tau pathology1. Introduction
Kallikrein-8 (KLK8, also known as neuropsin) is a synap-
tic plasticity-modulating extracellular serine protease [1,2].
Among other substrates KLK8 cleaves the ephrin receptor
B2 (EPHB2) and thereby induces various signaling
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protein-5 (FKBP5), which in turn regulates glucocorticoid
receptor sensitivity and provokes anxiety [3]. EPHB2
signaling via trans-cellular communication with ephrin B2
ligand (EFNB2) is further of particular relevance for
neuronal plasticity, as it coordinates axonal guidance [4]
and controls synaptogenesis [5]. EPHB2 signal transduction
is also known to induce angiogenesis [6] and autophagy [7,8]
under neoplastic conditions.
Given that all the aforementioned behavioral, molecular,
and structural processes, that is, anxiety and cognition,
neuronal [9,10], and vascular [11,12] plasticity, as well as
autophagy [13,14] are also impaired in Alzheimer’s
disease (AD) patients and transgenic mice, it seems likely
that KLK8/EPHB2 signaling could be involved in the
pathogenesis of AD, although hitherto very few studiesimer’s Association. This is an open access article under the CC BY-NC-ND
A. Herring et al. / Alzheimer’s & Dementia 12 (2016) 1273-12871274support this hypothesis.KLK8mRNA [15] is up-regulated in
AD-affected human hippocampus, and hippocampal EPHB2
is reduced in AD patients and in hAPP mice [16,17].
Lentivirus-mediated EPHB2 up-regulation improves cogni-
tion [18] and ligand-triggered EPHB2 activation diminishes
tau phosphorylation [19] in transgenic mice. Based on these
fragmentary results, we hypothesized that inhibition of
KLK8 and thereby reversing KLK8/EPHB2 imbalance
would mitigate AD pathology. Here, we demonstrate a
considerable up-regulation of KLK8, prior and in addition
to EPHB2 depletion, in human and murine brain at incipient
stages of AD, long before the “clinical” signs of disease
appear. We further show that 4 weeks of KLK8 inhibition,
by intraventricular delivery of an anti-KLK8 antibody after
disease onset, is sufficient to mitigate multiple features of
Alzheimer’s pathology in transgenic mice. Our data strongly
suggest that antibody treatment against KLK8 should be
tested in clinical trials for its potential against AD.2. Methods
2.1. General
All data presented in this article were generated in blind-
coded experiments, in which the investigators who collected
the data were unaware of the specific genotype and treatment
of mice, brain slices, and cell cultures. Protein, peptide, and
mRNA levels were quantified individually in duplicates or
triplicates in separate brain areas from mice and humans.
2.2. Descriptive approach2.2.1. Murine samples
Female TgCRND8 mice (hemizygously carrying and
over-expressing a double-mutant human APP 695 trans-
gene [hAPP1/2] harboring the “Swedish” and “Indiana”
mutations [KM670/671NL & V717F] under the control of
the hamster Prion protein promoter) [20] as well as wild-
type littermates from the hybrid C57BL/6-C3H/HeJ back-
ground strain were kept in standard housing in groups of
4 animals from postnatal day 30 (P30) until P360 in two in-
dependent batches. To minimize a biased effect of the
parental genotype on the phenotype of the investigated
mice, equal numbers of transgenic and wildtype mice
were used per litter. Brains from both genotypes were har-
vested at P30 (early juvenile period, before the onset of Ab
pathology, n 5 8 per genotype), P90 (around the onset of
Ab pathology, n 5 8 per genotype), P210 (advanced stage
of Ab pathology, n5 8 per genotype), and P360 (full-blown
stage of AD-like pathology, n5 8 per genotype). The brain
regions vulnerable for AD pathology and linked with AD-
related cognitive decline, that is, frontal cortex, entorhinal
cortex, and hippocampus as well as the lesser and later
affected cerebellum were isolated and used for DNA,
RNA, and protein extraction (15,596-018, TRIzol-reagent,
life technologies).2.2.2. Human samples
Frozen frontal cortices (gyrus frontalismedius), entorhinal
cortices, hippocampi, and cerebella from AD patients
classified (by two neuropathologists) as CERAD [21] A/
Braak & Braak [22] I–II (n 5 12, 5 females, 7 males,
73.92 6 1.94 years, postmortem interval (PMI)
35 6 3.97 hours), CERAD B/Braak & Braak III–IV (n 5 5,
5 females, 84 6 2.42 years, PMI 27.38 6 6.64 hours),
CERAD C/Braak & Braak V–VI (n5 7, 4 females, 3 males,
79.71 6 2.2 years, PMI 25.29 6 5.2 hours) as well as from
neurologically healthy young controls (n 5 6, 3 per sex,
30.67 6 2.97 years, PMI 31.33 6 10.18 hours), and age-
matched controls (n 5 10, 5 per sex, 65.6 6 2.62 years,
PMI 28.5 6 3.37 hours) were separately isolated and sub-
jected to DNA, RNA, and protein extraction. A list of all hu-
man samples is available in Supplementary Table 1.
2.3. Characterization of the anti-KLK8 antibody
Binding of the inhibitory anti-KLK8 antibody (1:200,
M021-3, MBL International) to recombinant human KLK8
(rhKLK8, 20 pmol/ml, 2025-SE-010, R&D Systems) and
to KLK8 from mouse brain homogenate (20 mg/sample)
was validated by immunoblotting. Specificity of the anti-
KLK8 antibody has been reported before, demonstrating
that it does not cross-react with other cerebral serine prote-
ases, such as a-thrombin, trypsin, kallikrein, tissue plasmin-
ogen activator, or urokinase plasminogen activator [23].
EPHB2 fragmentation by KLK8 was tested by incubation
of recombinant chimeric EPHB2-FC (400 ng at 100 ng/ml,
E9402, Sigma-Aldrich) with lysyl endopeptidase (0.01
A U./mg rhKLK8, 125-02,543, Wako) activated rhKLK8*
(4 ng at 1 ng/ml) and subsequent EPHB2 immunoblotting
(1:100, AF467, R&D Systems). The capacity of the anti-
KLK8 antibody to protect EPHB2 from fragmentation was
analyzed by incubation of 400-ng EPHB2-FC with 4-ng
rhKLK8* which was blocked by pre-treatment with 80 ng
anti-KLK8 antibody (at 20 ng/ml, rhKLK8*-block) in com-
parison to incubation of EPHB2-FC with rhKLK8* which
was pre-incubated with 80-ng isotype control rat IgG
(MCA1124R, AbD Serotec) and subsequent EPHB2 immu-
noblotting.
2.4. Experimental manipulations2.4.1. In vivo approach
2.4.1.1. Intraventricular anti-KLK8 antibody delivery
A total of 16 female transgenic mice and 16 female wild-
type littermates were standard housed in groups of 4 mice
from P30 until P150 in 3 independent batches. At P150, all
mice were subjected to subcutaneous implantation of os-
motic pumps (7147160-6, Alzet 2004, Durect) and brain
infusion kits (0008859-2, Alzet Brain Infusion Kit 3, Du-
rect). A hole was drilled in the stereotaxically correct
location (20.2 Bregma, 10.9 parasagittal), and a cannula,
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lateral ventricle and cemented in place, enabling constant
intraventricular delivery of the anti-KLK8 antibody
(M021-3, 62 mg/kg/d at an average concentration of
0.21 mg/ml diluted in saline and a flow rate of 0.25 ml/h,
n 5 8 per genotype), control rat IgG (MCA1124R, n 5 7
per genotype), or saline (n 5 1 per genotype) over a 4-
week period. Antibodies were dialyzed against sterilized
PBS, pH 7.4 to remove NaN3 (88,401, Slide-A-Lyzer Mini
Dialysis Devices, Thermo Scientific) before injection into
pumps. To minimize a biased effect of the parental genotype
on the phenotype of the experimental mice, littermates were
equally distributed to verum and control groups.
2.4.1.2. Behavioral phenotyping
From P178 until P184, mice were behaviorally pheno-
typed. Before testing, they had been adapted to the inverted
day/night cycle for 1 week. First, anxiety behavior was
evaluated in the Elevated-Plus Maze (EPM) according to
Young et al. [24]. The EPM consisted of two opposite
open arms (each 27.5 ! 6 ! 0.5 cm, length ! width !
height), two opposite closed arms (each 27.5 !
6 ! 16 cm) and a center platform (5 ! 5 ! 0.5 cm).
The maze was 75 cm elevated above the ground. Each
mouse was placed in the center and observed for 5 minutes.
Number of entries, latencies until first time entries, duration
and distance covered in closed and open arms, and in the
center as well as velocity were automatically tracked and
analyzed by Video Mot 3D software (TSE, version 7.0.1).
The next day, mice were tested in the open field (OF) for
exploratory behavior and general activity according to Kilic
et al. [25]. The OF arena (52! 52! 30 cm) was located
72 cm above the floor on a circular platform. Each mouse
was placed near the wall and observed for 10 minutes.
The test arena was divided into one center
(31.2 ! 31.2 cm), four border (each 10.4 ! 31.2 cm),
and four corner (each 10.4 ! 10.4 cm) areas. Number of
entries, latencies until first time entries, duration, and dis-
tance covered in each area as well as velocity were
automatically tracked. From P180 until P184,
hippocampus-associated spatial memory and learning per-
formance was assessed by the Barnes Maze (BM) according
to Sunyer et al. [26]. The BM arena consisted of a circular
platform (92 cm diameter, 120 cm above the ground) with
20 equally distributed holes (5 cm diameter, 7.5 cm distance
between holes) located at the border. One hole (escape hole)
was connected to a box (15.5! 9.5! 6 cm), allowing to
escape from the BM platform, whereas the other 19 holes
were closed (error holes). Twenty four hours before tests
started, mice were habituated to the setup for two trials,
each lasting for 3 min. Tests were performed between
10:00 am and 6:00 pm. Each mouse was placed in a black
cylinder located in the middle of the platform for 10 sec-
onds. During that time, red light was switched to bright
light (180 lx), and the cylinder was lifted, defining the start
of a 3-minute trial. During each trial, primary errors, totalerrors, primary latency, total latency, path length covered,
and velocity were automatically recorded. Primary errors
and latencies were defined as the number and duration of
approximations to error holes until approaching the escape
hole for the first time. Total errors and latencies were
defined as the number and duration of approximations to er-
ror holes and to the escape hole until final escape. Once a
mouse escaped, it was allowed to stay in the escape box
for 1 minute before being transferred to the home cage. If
a mouse did not escape during the 3-minute interval, it
was gently guided to the escape hole until the mouse
escaped; otherwise, it was placed directly into the escape
box for 1 minute. On test day 1, each mouse was tested in
four trials. On test days 2, 3, 4, and 5, each mouse was tested
in two trials. Inter-trial intervals lasted for 15 minutes. After
the four test days, the escape hole was blocked at day 5
(probe trial). Mice were allowed to explore the platform
for 90 sec per trial. In all behavioral tests, freezing and
exploration behavior were manually recorded. Before and
after each test, the EPM, OF, and BM arenas were cleaned
with 70% ethanol.
2.4.1.3. Blood and tissue sampling
After behavioral testing, blood was collected from retro-
bulbar venous plexus of each transgenic animal to deter-
mine baseline circulating plasma Ab levels. To quantify
Ab efflux efficacy across the brain-blood barrier (BBB),
7 anti-KLK8 antibody-treated, 6 IgG treated, and 1
saline-treated transgenic mouse received an intravenous
(tail vein) injection of an Ab stabilizing anti-Ab antibody
(HJ5.1, 150 mg/animal) (purchased from Dr. David M.
Holtzman’s laboratory, St. Louis, Missouri [27]) that only
marginally enters brain parenchyma and does not affect
the Ab-brain-to-blood-equilibrium to prevent the naturally
occurring rapid Ab degradation in blood (t1/2 5 2–3 mi-
nutes) which precludes a direct and sensitive quantification
of brain-derived Ab over baseline circulating plasma Ab.
1 anti-KLK8 antibody-treated versus 1 IgG-treated trans-
genic mouse received saline as control. 10 and 40 minutes
after HJ5.1-antibody or saline injection, blood was
collected again. Pump implantation, intravenous injection,
and retrobulbar venous blood collection was conducted in
anesthetized mice with 2% isoflurane in oxygen/nitrous ox-
ide (20%:40%) using a vaporizer. Afterward, mice were
sacrificed (in deep anesthesia). Frontal cortex, hippocam-
pus, amygdala (basolateral & central nuclei), and basal
ganglia were isolated and separately homogenized from
one hemisphere. Homogenates were subjected to DNA,
RNA, and protein extraction (TRIzol-reagent). From the
remaining intact hemisphere, the frontal pole (14 to
11.5 Bregma) was impregnated with Golgi-Cox solution
(PK401-A, FD Rapid GolgiStain Kit, FD NeuroTechnolo-
gies) and subsequently cut into 200-mm coronal sections.
The rest of the brain hemisphere was formalin-fixed,
paraffin-embedded, and cut into 10-mm coronal sections
for immunohistochemistry.
A. Herring et al. / Alzheimer’s & Dementia 12 (2016) 1273-128712762.4.2. In vitro approach
Between 14 days in vitro (DIV 14) and DIV 21, primary
mixed glial cell cultures (50%:50% microglia:astroglia)
from whole cerebrum of neonatal (P0) transgenic or wildtype
mice were characterized for the presence of extracellular and
intracellular KLK8 (1:200, ABIN759116, antibodies-online.
com) and for intracellular EPHB2 (1:100, AF467) via
immunoblot as well as for intraglial and extraglial Ab40
and Ab42 by ELISA (Ab40 and Ab42, KHB3482 and
KHB3442, Invitrogen).
At DIV17, primary mixed glia (50%:50% microglia:as-
troglia, 250,000 cells per well for lysates, 60,000 cells per
well for immunofluorescence cytochemistry, 100,000 cells
per well for autophagy monitoring, 150,000 cells per well
for cell viability monitoring) were incubated either with
anti-KLK8 antibody (M021-3) or control IgG antibody
(MCA1124R) at a concentration of 5 mg/mL (dialyzed
against PBS as described above). At DIV18, Ab42
(100 ng/mL, 72,071, SensoLyte Fluorescent Ab42 Sampler
Kit, Anaspec) as well as fresh antibody (2.5 mg/mL) were
added to the medium (41,966–029, DMEM, 16,050–122,
10% horse serum, 15,140–122, 1% penicillin/strepto-
mycin, all from Thermo Fisher Scientific). At DIV19
and DIV20, antibody but not Ab42 treatment was repeated.
Supernatant and cell lysates were collected at DIV 17 to
DIV 21. To test whether effects of anti-KLK8 antibody
treatment were transduced by the EPHB2 receptor, we
simultaneously co-incubated anti-KLK8-treated glial cells
with an inhibitory anti-EPHB2 antibody (2 mg/mL,
AF467, R&D Systems) (for experimental setting see also
Supplementary Fig. 4A).2.5. Outcome measures2.5.1. Descriptive approach
Protein levels of EPHB2 (1:100, AF467), EFNB2 (murine:
1:500, AF496, R&D Systems; human: 1:100, ab96264, ab-
cam), KLK8 (1:100, ABIN759116), FKBP5 (murine:
1:500, human: 1:200, ab2901, abcam), beclin-1 (1:2,000,
ab62557, abcam), and STX17 (1:1,000, 17,815-1-AP, Acris)
were quantified by immunoblot. Protein levels of GAPDH
(1:15,000, G9545, Sigma-Aldrich), actin b (1:15,000,
A5441, Sigma-Aldrich), or determination of total protein
load via fluorescent gel electrophoresis (TGX stain free
gels, 161-0183, Bio-Rad) served for normalization. Tran-
scription levels of murine and human KLK8, FKBP5,
EPHB2, and EFNB2 were measured via quantitative real-
time PCR (TaqMan assays, ABI 7500 Fast real-time PCR
cycler, Applied Biosystems) after reverse transcription of
DNase-treated RNA extracts to cDNA (ABI High-Capacity
RT Kit, #4368814, Applied Biosystems) and normalized
against GAPDH or cytochrome c1 (CYC1). Intron-spanning
forward and reverse primer sequences and the TaqMan probe
forward sequences are available on request.2.5.2. In vivo approach
Sufficient cerebral penetration of anti-KLK8 antibody or
control IgG antibody (both antibodies produced in rat) after
intraventricular delivery was validated in lysates from frontal
cortex, basal ganglia, hippocampus, andamygdalabyvisualiza-
tion of rat immunoglobulins with secondary anti-rat-HRP
antibody (1:5000,A9037, Sigma-Aldrich) via immunoblotting.
Protein levels of EPHB2 (1:100, AF467), synaptophysin
(1:10,000, M7315, DAKO), GAP43 (1:4000, GTX11136,
GeneTex), ARC (1:500, sc-15325, Santa Cruz Biotech-
nology), FKBP5 (1:500, ab2901), glucocorticoid receptor
(1:1000, ab109022, abcam), APP (and the processing frag-
ment CTFb, 1:2000, A8717, Sigma-Aldrich), MDR1
(1:1000, APO94346PU-N, Acris), LRP1 (1:500, 438192,
Calbiochem), RAGE (1:1000, SP5151P, Acris), beclin-1
(1:2000, ab62557, abcam), ATG5 (1:500, A0856, Sigma-
Aldrich), STX17 (1:1000, 17,815-1-AP, Acris), cathepsin
D (1:1000, ab6313, abcam) and prostaglandin E receptor 2
(1:500, APO01201PU-N, Acris) were determined by immu-
noblotting. GAPDH served for normalization. Tau phos-
phorylation levels at amino acids S202/T205 (1:500, AT8,
MN1020, Thermo Scientific), S396 (1:1000, PA5-35455,
Thermo Scientific) and T212/S214 (1:500, AT100,
MN1060, Thermo Scientific), PI3K phosphorylation at
T199/T458 (1:2,000, #4228, Cell Signaling Technology),
Akt phosphorylation at S473 (1:1000, #9271, Cell Signaling
Technology), GSK3b phosphorylation at S9 (1:1000, #9336,
Cell Signaling Technology) and total protein levels of tau
(1:500, tau-5, MAB361, Millipore), PI3K (1:500, #4257,
Cell Signaling Technology), Akt (1:1000, #9272, Cell
Signaling Technology), and GSK3b (1:2000, #9315, Cell
Signaling Technology) were quantified by immunoblotting
as well. Total protein levels of tau, PI3K, Akt, and GSK3b
as well as GAPDH served for normalization.
sAPPa (JP27734, IBL International), Ab40, and Ab42
peptide levels were quantified by ELISA in protein homog-
enates containing 1% SDS.
Transcription levels of hAPP were determined via quan-
titative real-time PCR and normalized against GADPH
mRNA levels. Primer and TaqMan probe sequences are
available on request.
For morphometric analyses, a Nikon 80i microscope with
an integrated CFI ocular lens (10!magnification), equipped
with CFI PLANACHROMATobjectives (2!magnification,
numerical aperture 0.06; 10!magnification, numerical aper-
ture 0.25), CFI PLAN FLUOR objectives (20! magnifica-
tion, numerical aperture 0.5; 40! magnification, numerical
aperture 0.75) and a PLAN APOCHROMAT VC objective
(100! magnification, numerical aperture 1.4) (all objectives
from NIKON), a color digital camera (3/400 chip, 36-bit color,
DV-20, MicroBrightField), and MicroBrightField software
were used. Ab plaques (1:100, 6F/3D, DAKO), microglia
(AIF1, 1:100, APO8912PU-N, Acris), and cerebral vessels
(laminin, 1:300, L9393, Sigma-Aldrich) were visualized and
stereologically quantified in 10 sections (with 100 mm inter-
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described [28] with minor modifications. Briefly, Ab plaque
load was quantified at 200! magnification. Ab plaque vol-
ume (i.e., percentage of cerebral volume covered by deposits)
and Ab plaque number (n/mm2) were calculated in an unbi-
ased manner by area fraction fractionator and fractionator
(counting frame and grid size, each 500! 500 mm), respec-
tively. The number ofmicroglia with a visible soma and blood
vessel bifurcations (n/mm2) [(vessel ends 1 vessel branch
point)/2] were determined at 200! magnification via frac-
tionator (counting frame 250 ! 250 mm, grid size
375 ! 375 mm). Additionally, 6 sections per animal were
co-stained forAb plaques andmicroglia. The average number
of plaques surrounding microglia was calculated using the
fractionator probe (counting frame 250! 250 mm, grid size
375 ! 375 mm) at 200! magnification. Absolute values
were related to the investigated area (Stereo Investigator 11,
MicroBrightField). Six sections per animal were co-stained
for Ab plaques and phosphorylated tau (1:80, AT8,
MN1020, Thermo Scientific). To determine the proportion
of neuritic plaques, the number of AT8-positive Ab plaques
was set in relation to the total number of Ab plaques (with
or without surrounding AT8-positive neurites) using the frac-
tionator probe (counting frame, 250 ! 250 mm; grid size,
375! 375 mm) at 200! magnification.
The effect of KLK8 inhibition on structural neuronal
plasticity was tested in Golgi-Cox impregnated coronal
sections. We analyzed 10 pyramidal neurons from layer
V frontal cortex (14 to11.5 Bregma) per animal. All api-
cal and basal dendrites extending from the neuron soma
were traced (Neurolucida 11, MicroBrightField) at
400! magnification for 3D reconstruction. To determine
dendritic spine density, spines were counted on four 20-
mm long dendritic segments per neuron, i.e. on a proximal
apical segment, on a distal apical segment, on a proximal
basal segment, and on a distal basal segment at 1000!
magnification. A proximal segment was defined to start
after the first dendritic branch point, a distal one after
the third branch point. To quantify apical and basal den-
dritic morphology, a morphometric analysis of dendritic
number, length, and branching complexity was per-
formed. Dendritic complexity was calculated by the for-
mula: [sum of the terminal orders 1 number of
terminals] ! [total dendritic length/number of primary
dendrites]; with terminals defined as dendritic endings
and the terminal order defined as the number of “sister”
branches encountered while proceeding from the terminal
to the cell body (NeuroExplorer, MicroBrightField).
2.5.3. In vitro approach
The influence of anti-KLK8 antibody on glial EPHB2
protection was validated by quantification of EPHB2-FL in
lysates using immunoblotting (1:100, AF467).
Anti-KLK8 antibody triggered autophagy modulation
was determined by beclin-1 (1:500, ab62557), ATG5
(1:500, A0856, Sigma-Aldrich), and STX17 (1:1,000,17,815-1-AP) immunoblot and via an autophagy assay
(600140, autophagy/cytotoxicity dual staining kit, Cayman
Chemical) after manufacturer’s instructions analyzed on a
fluorescence microplate reader (Flx800, BioTek).
Ab phagocytosis was determined by quantification of
Ab42 in glial lysates and supernatant by ELISA and micro-
glial Ab42 uptake visualized by fluorescent Ab42 and AIF1
immunofluorescence cytochemistry (1:100, APO8912PU-
N, Acris Antibodies).
Cell viability was monitored after manufacturer’s instruc-
tions (9095S, XTT cell viability kit, Cell Signaling Technol-
ogy). Wildtype and transgenic cells were examined
separately. Owing to lack of significant differences, data of
both genotypes were pooled.2.6. Statistics
Data are presented as means 6 SE. Distribution of all
data sets was evaluated by 1-sample Kolmogorov–Smir-
nov test and Q-Q plots. Homogeneity of variance was
calculated with the Levene test. Student t test with Bonfer-
roni correction for multiple testing was applied for the an-
alyses of two groups. For the descriptive approach,
multiple groups comparison was analyzed by 2-way anal-
ysis of variance (ANOVA) with aging (in mice: P30–P360,
in humans: young vs. old) and murine genotype (transgene
vs. wildtype) or human disease status (AD vs. control) as
between-subject factors and Bonferroni post hoc test. For
the experimental in vivo approach, multiple groups’ com-
parison was analyzed by 2-way ANOVA with treatment
(verum vs. control) and genotype (transgene vs. wildtype)
as between-subject factors and Bonferroni post hoc test.
Cell culture experiments were analyzed by 2-way AN-
OVA with treatment (verum vs. control) and time as
between-subject factors and Bonferroni post hoc test.
Pearson-correlation analysis was performed to test the
strength of association between protein levels of KLK8/
EPHB2 signaling members. A significance level (a) of
P , .05 was selected. All tests were performed using the
software package SPSS 22 (IBM).2.7. Ethical considerations
All animal experiments were carried out in accordance
with the EU Directive 2010/63/EU for animal experiments.
Permission for mice breeding and decapitation (AZ 84-
02.04.2014.A488) as well as for animal experiments
(G1338/12; AZ 84-02.04.2012.A412) was granted by the
local committee LANUV NRW, Germany.
Using postmortem human material was approved by the
ethics committees of the Medical Faculties, University of
Duisburg-Essen, (14-5861-BO) and Ludwig-Maximilians-
University Munich (#345-13), Germany. Written informed
consent was received from the family members of the dead
patients before inclusion in the study.
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3.1. KLK8 overexpression in precursor stages of AD
First, we assessed the temporal and spatial mRNA and
protein expression patterns of KLK8, and its downstream
cascade members EPHB2, FKBP5, and EFNB2 during the
course of AD progression in the hippocampus, frontal cor-
tex, entorhinal region, and cerebellum of both transgenic
CRND8 and wildtype mice as well as AD patients and in
neurologically healthy (young and old) controls. In partic-
ular, in the hippocampus (Fig. 1), KLK8 protein levels
were increased long before disease onset at P30 in transgenic
mice (Fig. 1A and 1B) when compared to age-matched con-
trols. Presumably due to decline of neuroplasticity processes
in the aging brain, there was an age-related KLK8 drop in
both mouse genotypes (reaching a steady state level in trans-
genics after P90 and in wildtypes after P210). In spite of this
drop, KLK8 levels remained throughout all ages almost
constantly higher in transgenics than in wildtypes. In AD pa-
tients, hippocampal KLK8 levels were already higher at
CERAD A/Braak I–II stage when compared to aged-
matched controls (Fig. 1C and 1D); KLK8 level increased
further with AD progression (CERAD A/Braak I–II to
CERAD C/Braak V–VI, Fig. 1C and 1D). Owing to lack
of appropriate samples, we cannot make any statements on
the course of KLK8 expression in severer stages of pathol-
ogy in mice (e.g., in P540 or older), and it remains also un-
clear whether KLK8 levels are, as it is the case in mice,
already elevated in infant brains of future AD patients. It is
tempting to speculate that this, at least in familiar AD cases
could be true. A disease-related KLK8 overabundance could
be detected also in other brain regions, that is, the frontalFig. 1. KLK8 overexpression at incipient stages of AD precedes the depletion o
EPHB2, FKBP5, and EFNB2 in young (P30), adolescent (P90), adult (P210), and
expression of KLK8, EPHB2, FKBP5, and EFNB2 in AD patients at CERADA/Br
and old controls. A combined quantification of the pro-form of KLK8 and activate
***P , .001 (2-way ANOVA and Bonferroni post hoc test). Black asterisks indica
comparison between different disease and age stages within diseased or control g
shown as mean 6 SEM.cortex, entorhinal cortex, and even cerebellum
(Supplementary Fig. 1) of both species. KLK8 overexpres-
sion was followed by a reduction of full-length EPHB2
(EPHB2-FL) receptor levels in the hippocampus of trans-
genic mice at P210 (Fig. 1A and 1B) and in patients with
moderate AD at CERAD B/Braak III–IV stage (Fig. 1C
and 1D). EPHB2 levels declined also in the murine cere-
bellum and human frontal cortex but not in the entorhinal
cortex (Supplementary Fig. 1). FKBP5 protein levels were
elevated in the frontal, entorhinal, and cerebellar cortex
(Supplementary Fig. 1) as well as in the hippocampus very
early at P30 in transgenic mice and at CERAD A/Braak I–
II stage in humans but declined during the course of disease
(Fig. 1A–1D). EPHB2 ligand EFNB2 was down-regulated
during disease progression, in the murine hippocampus
(Fig. 1A and 1B) and displayed reduced entorhinal and cere-
bellar levels, only in the later stages of disease in mouse
(P210) and man (CERAD C; Supplementary Fig. 1).
The exceedingly early andmultifocal up-regulation of the
protease KLK8, even in the scarcely AD-affected cere-
bellum not only explains the subsequent decline of its pro-
teolytic target EPHB2 (supported also by a strong negative
correlation between hippocampal KLK8 and EPHB2 protein
levels, r520.663, P, .001) but also suggests a causal role
in the cascade of events leading to AD. We therefore sought
to verify whether inhibiting the proteolytic enzyme KLK8
would mitigate Alzheimer’s pathology.3.2. Anti-KLK8 antibody inhibits KLK8 activity
We first confirmed that anti-KLK8 antibody, but not the
isotype control IgG, specifically (i.e., with no cross-f its proteolytic target EPHB2. (A–B) Hippocampal expression of KLK8,
old (P360) transgenic (TG) and wildtype (WT) mice. (C–D) Hippocampal
aak I–II, CERADB/Braak III–IV, CERADC/Braak V–VI stages, and young
d KLK8* is depicted for murine and human samples. *P , .05, **P , .01,
te comparison between diseased and control groups, gray asterisks indicate
roups. n 5 8 per murine group and n 5 5–12 per human group. Results are
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man and murine KLK8 (Supplementary Fig. 2A). The
functionality of this antibody was tested by examining
the cleavage efficiency of KLK8 on its substrate EPHB2
whose processing results in a 70-kDa extracellular, N-ter-
minal fragment (EPHB2-NTF) [3]. After proving that
EPHB2 is cleaved by KLK8 in a cell free in vitro assay
(Supplementary Fig. 2B and 2C), we demonstrated that
the anti-KLK8 antibody is able to protect EPHB2 from
fragmentation both in the cell free assay (Supplementary
Fig. 2B and 2C) and in primary glial cell culture
(Supplementary Fig. 2D and 2E). To test the inhibitory ef-
ficacy of the anti-KLK8 antibody in vivo, anti-KLK8 anti-
body, control IgG, or saline was intraventricularly
delivered over a 4-week period to 150-day old transgenic
and wildtype mice using osmotic pumps (for experimental
setting see also Fig. 2A). After confirmation of sufficient
cerebral antibody penetration (Supplementary Fig. 2F),
quantification of EPHB2-FL revealed that anti-KLK8
antibody treatment successfully blocked EPHB2 cleavage
(Supplementary Fig. 2G and 2H). During the treatment
period, none of the mice exhibited any signs of adverse re-
action. Body mass were not affected by treatment (data
not shown).3.3. KLK8 inhibition reduces fear and improves cognition
Progressive cognitive decline and increased anxiety are
the clinical hallmarks of AD. Previous studies demon-
strated that KLK8-triggered amygdalar EPHB2 fragmenta-
tion controls anxiety [3], that lentivirus-mediated EPHB2
up-regulation reduces cognitive impairment in transgenic
AD mice [18] and that high concentrations of KLK8 impair
hippocampal long-term potentiation and induce long-term
depression ex vivo [29]. We therefore postulated that cere-
bral KLK8 inhibition (and subsequent EPHB2 protection)
might exert anxiolytic effects and improve memory perfor-
mance in transgenic brains characterized by abnormally
high KLK8 levels. Accordingly, after 4 weeks of antibody
delivery, mice were phenotyped for anxiety-related
behavior in the EPM, for avoidance and exploratory
behavior in the OF and for spatial memory in the BM; for
experimental design see Fig. 2A. Automated video tracking
analysis substantiated that antibody-mediated cerebral
KLK8 inhibition has anxiolytic effects and increases
exploratory behavior in transgenic mice, as anti-KLK8
antibody-treated animals spent more time in the open
arms and less time in the closed arms of the EPM
(Fig. 2B and 2C), spent more time in the center and border
areas and less time in the corners of the OF arena (Fig. 2E
and 2F), took less time to enter the center area for the first
time (Fig. 2H), and showed reduced freezing and increased
exploratory behavior (Fig. 2I), when compared to controls
(IgG & saline). Evaluation of the BM further revealed that
blockade of KLK8 improved spatial memory performance
in AD-affected mice, as verum-treated transgenics hadreduced latencies (Fig. 2J–2L), explored fewer wrong holes
(Fig. 2M and 2N), and covered shorter distances (Fig. 2O
and 2P) before escaping through the escape hole at trial 1
on test day 1 (24 hours after 2 trials of habituation) as
well as on test day 4. Cognitive improvement through
KLK8 blockade was not accompanied by changes in motor
skills, as the average speed did not differ between the two
transgenic groups (data not shown). Wildtype control
mice (treated with IgG or saline) showed less anxiety,
more exploration activity (Fig. 2B–2I), and better cognitive
performance (Fig. 2J–2P) when compared to transgenic
control mice. In contrast to the positive effects of anti-
KLK8 antibody administration to transgenics, wildtype
mice barely benefited from this treatment. Although anti-
KLK8 treatment elicited anxiolytic effects also in wild-
types, as they spent less time in the closed arms of the
EPM (Fig. 2B and 2C) and exhibited increased exploratory
behavior in the OF (Fig. 2E and 2I), their memory perfor-
mance deteriorated significantly in the BM. Verum-
treated mice showed increased latencies (Fig. 2J–2L),
explored more wrong holes (Fig. 2M and 2N), and covered
longer distances (Fig. 2O and 2P) before escaping through
the escape hole at trial 1 on test day 1 and on test day 4.
Cognitive impairments were accompanied by a tendency
to hyperactivity, indicated by increased total distance trav-
elled in the EPM, OF, and BM arenas (Fig. 2D and 2G, P).
The mild adverse reactions occurring in wildtypes (ex-
pressing KLK8 at physiological levels) underlines, that
only individuals with pathological high KLK8 levels bene-
fits from this therapy. This is in line with a previous study
which has demonstrated that KLK8 reduction beneath or
rise above physiological levels both impairs spatial mem-
ory performance in wildtype mice [29].3.4. KLK8 inhibition reverses the molecular signatures of
anxiety and enhances structural neuroplasticity
Next, we verified the effect of anti-KLK8 antibody treat-
ment on molecular and structural signatures of anxiety and
cognition. The first step was to quantify the protein levels
of anxiety-modulating FKBP5 and glucocorticoid receptor
in the amygdala (as published in [3]) and in the frontal cor-
tex (an area which is not ostensibly involved in anxiety con-
trol). In line with the anxiolytic effect of KLK8 inhibition,
anti-KLK8 antibody treatment strongly suppressed FKBP5
and glucocorticoid receptor expression in the amygdala of
both transgenic and wildtype mice (Fig. 3A and 3B). In the
frontal cortex, antibody administration influenced neither
FKBP5 nor glucocorticoid receptor expression (Fig. 3C
and 3D). In the next step, we measured the protein levels
of structural neuroplasticity markers synaptophysin
(SYP), GAP43, and ARC in the hippocampus and frontal
cortex. In both transgenic (but not wildtype) brain areas,
KLK8 inhibition increased the expression of the synapto-
genesis and growth cone markers SYP and GAP43 (but
not ARC, Fig. 3E–3H). Accordingly, we determined the
Fig. 2. KLK8 inhibition reduces fear and improves cognition. (A) Anti-KLK8 treatment scheme. At P150 (2 months after disease onset), 16 female transgenic
(TG), and 16 female wildtype (WT) mice were subjected to subcutaneous implantation of osmotic pumps, enabling constant intraventricular delivery of either
the anti-KLK8 antibody (a-KLK8) (n5 8 per genotype), IgG (n5 7 per genotype), or saline (n5 1 per genotype) over a 4-week period. At P178, mice were
tested in the Elevated-PlusMaze (EPM) for anxiety, at P179 in the Open Field (OF) for exploratory behavior and between P180 and P184 for spatial memory and
learning performance in the BarnesMaze (BM). At P185, TGmice received an intravenous injection of an anti-Ab antibody (a-Ab) or saline, followed by blood
and brain tissue collection. (B, E, J) Representative paths from the EPM (B), the OF (E), and the BM (test day 1 [d1], trial 1 [t1], J). (C) Total time mice spent in
the center area, open arms, and closed arms of the EPM platform. (D) Total distance mice travelled in all three compartments of the EPM. (F) Total time mice
spent in the center area, borders, and corners of the OF platform. (G) Total distance mice travelled in all three compartments of the OF. (H) Time it took mice to
enter the center area of the OF for the first time. (I) Total time mice showed freezing or exploring behavior in the OF. (K, M, O) Learning curves during spatial
training in the BM. Total time (K, L), number of wrong holes approached (M, N), and total distance (O, P) mice needed to escape from the BM platform on d1–t1
and d4 (L, N, P). TP , .1, *P , .05, **P , .01 (2-way ANOVA and Bonferroni post hoc test). n 5 8 per genotype and treatment. Results are shown as
mean 6 SEM.
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Golgi-Cox-impregnated pyramidal neurons from layer V
frontal cortex (using Neurolucida and Neuro Explorer soft-
ware) and could corroborate increased spine density in
anti-KLK8 antibody-treated transgenics (but not wild-
types; Fig. 3I1-2, J), as well as elevated dendritic
complexity after cerebral KLK8 blockade in both geno-
types (Fig. 3I3-6, K-M).3.5. KLK8 blockade counteracts Ab pathology
To determine whether blockade of KLK8 might reverse
AD-related Ab pathology, we investigated APP metabolism
and Ab plaque pathology in the frontal cortex and in the later
and less affected basal ganglia. In both areas, four weeks of
anti-KLK8 antibody administration increased APP-FL
levels (without affecting the transcription of the hAPP
Fig. 3. KLK8 inhibition reverses the molecular signatures of anxiety and enhances structural neuroplasticity. Levels of anxiety-modulating FKBP5 and gluco-
corticoid receptor in the amygdala (A, B) and frontal cortex (C, D) of transgenic (TG) and wildtype (WT) mice treated with IgG or anti-KLK8 antibody (a-
KLK8). Levels of structural plasticity markers SYP, GAP43, and ARC in the hippocampus (E, F) and frontal cortex (G, H) of TG andWTmice treated with IgG
or a-KLK8. (I) Representative image of a Golgi-Cox-impregnated layer V frontal cortex neuron (image 1) and a magnified dendrite with spines (image 2) from
the same neuron (indicate by the red rectangle). Scale bar: 5 mm. Representative images (images 3–6) of digital reconstructions from Golgi-Cox-impregnated
neurons from all four murine groups. (J) Quantification of the average apical proximal and distal as well as basal proximal and distal spine density. The average
number of branches (K), the average length (L), and the complexity index (M) of apical, basal, and total dendrites per neuron was determined in the same neu-
rons. TP , .1, *P , .05, **P , .01 (2-way ANOVA and Bonferroni post hoc test). n 5 8 per genotype and treatment. Results are shown as mean 6 s.e.m.
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and Ab42 peptide concentration, whereas Ab40 and sAPPa
peptide levels remained unaffected (Fig. 4A–4E). These re-
sults indicate that blockade of KLK8 impedes amyloido-
genic APP processing. We then tested whether changes in
APP metabolism led to changes in Ab plaque burden. Ste-
reological quantification revealed that in the basal ganglia,
KLK8 blockade diminished the total volume and average
size (but not the total number) of diffuse Ab plaques (which
gradually evolve into core plaques) without affecting the
load of the longer established core plaques, whereas in the
frontal cortex, plaque load remained unchanged (Fig. 4F–
4J). The fact that anti-KLK8 antibody treatment affected
only those plaques with a younger history in the plaque
ontogeny implies that KLK8 inhibition interferes with early
steps in the amyloid cascade. Taken together, only 4 weeks
of KLK8 inhibition is capable to suppress amyloidogenic
APP processing and the subsequent Ab production, therebycounteracting Ab aggregation into diffuse plaques, at least in
brain areas which are not yet tightly littered with amyloid
deposits.3.6. KLK8 inhibition improves neurovascular function
As EPHB2 induces angiogenesis [6], we hypothesized
that cerebral KLK8 inhibition and the subsequent protection
of EPHB2 from fragmentation might have improved the
function of the neurovascular unit. Stereologic evaluation
of cerebral blood vessel branching in the frontal cortex and
basal ganglia (hereafter referred to as cerebral) revealed a
pro-angiogenic effect of KLK8 inhibition, only in wildtype
mice but not in the transgenics (Fig. 4K and 4L). Next, we
determined the impact of KLK8 inhibition on the cerebral
expression pattern of the BBB-located Ab efflux-
conducting LRP1 and MDR1 (also known as P-glycoprotein
1), and the Ab influx receptor RAGE. RAGE did not change
Fig. 4. Anti-KLK8 antibody treatment counteracts Ab pathology and improves neurovascular function. (A) hAPPmRNA levels in the frontal cortex and basal
ganglia of transgenic (TG) mice treated with IgG or anti-KLK8 antibody (a-KLK8). Full-length APP (APP-FL) and C-terminal fragment b (APP-CTFb) levels
(B, C), Ab42, and Ab40 (D), and sAPPa peptide levels (E) in the frontal cortex and basal ganglia of IgG or a-KLK8-treated TG mice. (F) Anti-Ab immuno-
staining of basal ganglia showing diffuse (black arrows) and core (white arrows) Ab plaque burden in TG IgG (left) and TG a-KLK8 (right) mice. Scale bar:
200 mm. Stereological quantification of total diffuse (G) and core (H) plaque volume, as well as of the average plaque size (I) and the total plaque number (J) in
the frontal cortex and basal ganglia. (K) Representative cerebral anti-laminin immunostaining of TG and wildtype (WT) mice treated with IgG or a-KLK8.
Scale bar: 100 mm. (L) Stereological quantification of cerebral (frontal cortex and basal ganglia) blood vessel branches. (M, N) Cerebral levels of Ab transporters
LRP1, MDR1, and RAGE from IgG or a-KLK8-treated TG andWTmice. (O) Ab efflux dynamics across the blood-brain-barrier (BBB) were determined over
various time spans (t05 0minutes, before anti-Ab antibody [a-Ab] injection, baseline plasma Ab levels, t105 10minutes after a-Ab injection and t40).
TP, .1,
*P , .05, **P , .01, ***P , .001 (Student t test and Bonferroni correction for comparison of two groups, 2-way ANOVA and Bonferroni post hoc test for
multiple groups’ comparison). n 5 8 per genotype and treatment. Results are shown as mean 6 SEM.
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increase of vessel density. Cerebral LRP1 andMDR1 protein
levels increased (the first one in transgenics by trend) after
anti-KLK8 antibody delivery (Fig. 4M and 4N), suggesting
facilitated elimination of cerebral Ab via BBB-mediated
clearance. To directly test this hypothesis, we determined
the kinetics of Ab efflux from the brain to blood in trans-
genics, using a modified protocol from Castellano et al.
[27]. 10 and 40 min (5t10 and t40) after intravenous injection
of an Ab stabilizing anti-Ab antibody (HJ5.1, enters brain
parenchyma only marginally, does not affect the Ab-brain-
to-blood-equilibrium, and protects Ab from enzymatic
digestion), blood plasma Ab40 and Ab42 levels were deter-
mined. Anti-KLK8 antibody treatment increased plasma
Ab40 at t10 (and at t40 by trend) as well as Ab42 at t40, indi-
cating improved Ab clearance across the BBB (Fig. 4O).3.7. KLK8 blockade induces autophagy and Ab
phagocytosis
Autophagy-controlled intracellular clearance of organ-
elles, proteins, and peptides is impaired in the brains of
AD patients [13] and transgenic mice [14]. EPHB2 induc-
tion appears to promote autophagy under neoplastic condi-
tions [7,8]. We therefore asked whether KLK8 inhibition
and the resulting EPHB2 protection are able to counteract
autophagy deficits in the AD-affected brain. First, we
corroborated an AD-related cerebral perturbation of auto-
phagy modulators, that is, beclin-1, involved in the initiation
of autophagosome assemblies [30], and STX17, a protein
that triggers fusion of autophagosomes with lysosomes
[31] in both mouse (Supplementary Fig. 3A and 3B) and
man (Supplementary Fig. 3C and 3D).
Fig. 5. KLK8 inhibition boosts the autophagy machinery and microglial Ab phagocytosis in murine brain and in vitro. Levels of beclin-1, ATG5 and STX17 in
IgG, and anti-KLK8 antibody-treated (a-KLK8) transgenic (TG) and wildtype (WT) mice in the frontal cortex (A, B) and basal ganglia (C, D). (E, F) Cathepsin
D levels in the frontal cortex and basal ganglia of TG andWTmice after IgG or a-KLK8 treatment. (G) Representative anti-cathepsin D immunostaining of the
frontal cortex in TG mice treated with IgG (left image) or a-KLK8 (right image) demonstrate reduced cathepsin D accumulation after KLK8 blockade. Scale
bar: 100 mm. (H) Primary glia were plated (astrocytes:microglia5 1:1) at DIV15. At DIV17 (before treatment, d0), expression and secretion of KLK8 (upper
images) and EPHB2 in its long (FL-L), short (FL-S) splice variants and in secreted form EPHB2-NTF (lower images) were determined in lysates and super-
natant. From d0 until d5, glia cells were either incubated with a-KLK8 or with IgG. Ab42 was added to the supernatant at d1. 8h later, as well as between d2 and
d6, lysates and supernatant were collected. (I, J) Intraglial beclin-1, ATG5, and STX17 levels between d0 and d4. (K) Fluorescence emission after glial treatment
with monodansylcadaverine (MDC, a probe detecting autophagic vacuoles) between d1 and d6. (L) After incubation with Ab42-FAM and MDC, a-KLK8-
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ATG5 (essential for the autophagosome assembly [32]) and
STX17 in anti-KLK8 antibody versus IgG-treated mice. In
transgenics (and to a lesser extend in wildtypes), KLK8 in-
hibition elevated the levels of beclin-1 and ATG5 in the fron-
tal cortex and basal ganglia (Fig. 5A–5D). By rescuing the
autophagy machinery, anti-KLK8 antibody treatment also
reversed the cortical accumulation of intraneuronal
cathepsin D (Fig. 5E–5G) —a lysosomal enzyme, which
(as shown also by others [33,34]) is present in excess in
murine and human AD-affected brain. The levels of
cathepsin D were lower in the basal ganglia per se and re-
mained unaffected by treatment (Fig. 5E and 5F).
Impaired Ab phagocytosis and dysfunctional beclin-1-
associated autophagy in the AD-affected brain is tightly
linked to reduced microglial activity [35]. Accordingly, we
examined the effect of anti-KLK8 antibody treatment on pri-
mary transgenic and wildtype microglial/astroglial co-
cultures (for experimental design see Supplementary
Fig. 4A) after demonstrating KLK8 secretion and EPHB2
expression (but virtually no Ab generation) in these na€ıve
cells (Fig. 5H). Although incubation with Ab42 (at d1)
knocked down the expression levels of glial autophagy
molecules beclin-1, ATG5, and STX17 and weakened fluo-
rescence emission in the autophagy assay, simultaneous
co-treatment with anti-KLK8 antibody protected the auto-
phagy machinery in both transgenic and wildtype glial cells
(Fig. 5I–5L). Of note, anti-KLK8 antibody treatment
doubled intramicroglial Ab42 levels (co-localizing with mi-
croglial marker AIF1, Fig. 5M and 5O), whereas Ab42 levels
in the supernatant were reduced when compared to IgG con-
trol (Fig. 5N and 5O), pinpointing an enhanced clearance of
extracellular Ab42 via microglial phagocytosis.
To test whether the positive effects of KLK8 inhibition on
autophagy protection and Ab clearance were transduced by
EPHB2 receptor, we co-incubated anti-KLK8 antibody-
treated glial cells with an EPHB2 inhibitory antibody (previ-
ously used in [3]). In spite of anti-KLK8-antibody presence,
inhibition of EPHB2 abolished autophagy and reduced mi-
croglial Ab clearance to levels indistinguishable from or
even, below IgG control treated cells, underlining the deci-
sive role of EPHB2 in this context (Supplementary
Fig. 4B–4G). Prolonged cell viability monitoring for up totreated glia (five images on the right) demonstrate increasedMDC incorporation, in
glia (five images on the left) at d6. Scale bar: 100 mm. Microglia depicted in the sm
Ab42-FAM in the IgG group and smaller autophagic vacuoles in a-KLK8-treated gl
and d4. (O) Fluorescence images of IgG (upper row) and a-KLK8-treated (lower row
AIF1 signal and hencemicroglial activation, increased intra-microglial Ab42-FAM,
enhanced Ab phagocytosis. Scale bars: 100 mm (upper image) and 10 mm (lower i
treated TG and WT mice. Scale bar: 500 mm. (Q) Stereological quantification of m
anti-Ab double immunostaining of basal ganglia of IgG or a-KLK8-treated TGmic
frontal cortex and basal ganglia. Cerebral expression of the pro-inflammatory PT
cortices; [V, W] in the basal ganglia), with PTGER2 levels being increased in fro
(2-way ANOVA and Bonferroni post hoc test). n 5 8 per murine group. n 5 6–8
and test day. Data represent the mean 6 s.e.m.11 days of treatment revealed that neither anti-KLK8 anti-
body nor anti-EPHB2 antibody affected glial survival or pro-
liferation (Supplementary Fig. 4H). A genotype-specific
difference in basal autophagy and Ab phagocytosis efficacy
could not be detected in primary glia (data not shown),
supporting the data of previous publications that microglial
functional impairment coincides with amyloid deposition
and does not precede it [36].
Next, we searched for evidence of an enhancedmicroglial
Ab phagocytosis triggered by KLK8 inhibition in vivo. Ste-
reological quantification revealed an increase in the total
number of activated AIF1-positive microglia in the basal
ganglia (but not frontal cortex) of transgenic (but not wild-
type) mice (Fig. 5P and 5Q). Additionally, the average num-
ber of microglia per plaque was elevated in the basal ganglia
(but not in frontal cortex) in verum-treated transgenics
(Fig. 5R and 5S). As the expression of the pro-
inflammatory prostaglandin E receptor 2 (PTGER2) was
not affected by anti-KLK8 antibody treatment (Fig. 5T–
5W), the utilization of anti-KLK8 antibody seems to pro-
mote the proliferation of phagocytic rather than cytotoxic
microglia, plaque approximation, and subsequent Ab uptake
also in vivo. Together, our in vitro and in vivo data strongly
support that KLK8 inhibition induces autophagy and Ab
clearance via microglial phagocytosis.3.8. KLK8 blockade counteracts tau pathology
Although TgCRND8 mice are not a model of primary tau
pathology, they display abnormal tau processing as a conse-
quence of Ab pathology [37]. As it has been recently shown
that ligand-triggered stimulation of EPHB2 attenuates tau
hyperphosphorylation in tau-transgenic mice [19], we next
examined whether KLK8 inhibition and subsequent
EPHB2 restoration might reverse Ab-related tau hyperphos-
phorylation in TgCRND8 mice as well. We found that 4
weeks of anti-KLK8 antibody administration reduced the ra-
tio of neuritic plaques (containing phospho-tau positive
dystrophic neurites) in relationship to total number of Ab
plaques (Fig. 6A and 6B) and lessened tau phosphorylation
at amino acids S202/T205, S396, and T212/S214 (Fig. 6C
and 6D). The neuroprotective effect of anti-KLK8 therapy
against tau hyperphosphorylation was mediated bydicating increased autophagic vacuole density when compared to IgG-treated
aller images demonstrate swollen autophagic vacuoles heavily loaded with
ia. Scale bar: 10 mm. Intraglial (M) and extraglial (N) Ab42 levels between d0
) glia incubatedwith Ab42-FAM and a-AIF1 at d2, demonstrating increased
and reduced extra-glial Ab42-FAM signal in a-KLK8-treated glia, indicating
mage). (P) Anti-AIF1 immunostaining of basal ganglia of IgG or a-KLK8-
icroglial density in the frontal cortex and basal ganglia. (R) Anti-AIF1 and
e. Scale bar: 100 mm. (S) Number of microglia surroundingAb plaques in the
GER2 remained unchanged after a-KLK8 treatment ([T, U] in the frontal
ntal cortices of diseased mice. TP , .1, *P , .05, **P , .01, ***P , .001
cell culture plates from three independent batches per treatment condition
Fig. 6. Anti-KLK8 antibody treatment counteracts tau pathology. (A) Anti-phospho-tau (AT8) and anti-Ab double immunostaining showing neuritic, AT8-
positive (black arrows) and non-neuritic, AT8-negative (white arrows) Ab plaques in the frontal cortex of transgenic (TG) mice treated with IgG or anti-
KLK8 antibody (a-KLK8). Scale bar: 100 mm. (B) Stereological quantification of the neuritic to total plaque ratio in the frontal cortex and basal ganglia.
(C, D) Levels of tau phosphorylation at S202/T205, S396, and T212/S214 normalized against total tau amounts and GAPDH. (E, F) Levels of PI3K phosphor-
ylation at T199/T458, Akt phosphorylation at S473 and GSK3b phosphorylation at S9, normalized against levels of total PI3K, Akt or GSK3b, and GAPDH.
*P , .05, **P , .01, ***P , .001 (Student t test and Bonferroni correction for multiple testing). n 5 8 per treatment. Results are shown as mean 6 SEM.
A. Herring et al. / Alzheimer’s & Dementia 12 (2016) 1273-1287 1285activation of PI3K (indicated by increased phosphorylation
of PI3K at T199/T458) as well as Akt (indicated by
increased phosphorylation of Akt at S473) and thus down-
stream inhibition of GSK3b (indicated by increased phos-
phorylation of GSK3b at S9; Fig. 6E and 6F).4. Discussion
In line with the limited prior research in this area [15–17],
we demonstrate here an AD-related KLK8 excess and
EPHB2 deficit in both murine and human hippocampi. We
now expand these findings to show a sustained surplus of
KLK8 mRNA and protein in different brain regions, both
in AD-affected and rarely affected brain areas such as the en-
torhinal cortex and cerebellum, respectively. Besides consid-
erable similarities in the (pathologic) expression patterns of
KLK8 and its downstream signaling molecules EPHB2/
FKBP5/EFNB2 in mouse and man, there were also some
interspecies discrepancies which are explicable through spe-
cies differences per se, differences in the disease genetic
background (early onset familiar AD mouse model with
hAPPSwedish/Indiana mutations vs. late-onset sporadic AD pa-
tients) and most importantly age and disease stage differ-
ences (with mice being examined at P30/P90/P210/P360
which equate to childhood/adolescence/middle-aged and/
or old aged and humans at on average 75 years of age in
the AD and old control groups and 31 years in young control
group). Of note, the interspecies match was highest for
KLK8 followed by its proteolytic substrate EPHB2 and the
downstream signaling molecule FKPB5, and lowest for
EFNB2. Irrespective of these differences, KLK8 excess oc-curs in both species very early in the course of the disease
and before the depletion of its proteolytic target EPHB2,
that is, in mice before Ab pathology onset and in humans
in preclinical stages.
This exceedingly early and multifocal event is suggestive
of a key and causative role for KLK8 in the pathogenesis of
AD. To our knowledge, our study is the first to provide evi-
dence that the inhibition of KLK8 attenuates multiple pri-
mary and secondary dysfunctions evolving during the
course of AD. We show that KLK8 blockade in TgCRND8
mice diminishes amyloidogenic APP processing, improves
neurovascular function andAb clearance across the BBB, en-
hances microglial Ab phagocytosis and autophagy, and
thereby reduces cerebral Ab load. It further suppresses tau
phosphorylation signaling and reverses abnormal tau phos-
phorylation. In addition to targeting Ab and tau metabolism,
down-regulation of KLK8 activity normalizes the molecular
signatures of anxiety in the amygdala and induces structural
neuroplasticity in the hippocampus, resulting in less fearful
behavior and better memory performance in transgenic mice.
Further work should investigate which of the molecular,
structural, and behavioral improvements are immediate con-
sequences of KLK8 blockade, secondary effects of EPHB2
protection, or tertiary signs of integral amelioration. For
example, the effects on the autophagy machinery and micro-
glial Ab clearance appear to be directly attributable to anti-
KLK8 treatment and EPHB2 dependent. Treatment-induced
anxiolytic effects are probably also the immediate conse-
quence of reduced KLK8 activity and diminished EPHB2
fragmentation, resulting in FKBP5 and glucocorticoid re-
ceptor suppression, a mechanism first described by Attwood
A. Herring et al. / Alzheimer’s & Dementia 12 (2016) 1273-12871286et al. [3]. Attenuated tau pathology, however, is likely to be
in part a direct consequence of anti-KLK8-triggered sup-
pression of tau phosphorylation signals but also an indirect
result of Ab decline and reduced neurotoxicity. Likewise,
the effects of anti-KLK8 treatment on Ab generation/Ab ag-
gregation/neurovascular dysfunction could arise from im-
mediate affecting of only one member of this loop and
subsequently indirect influencing of the other components
by breaking the ongoing “vicious circle”. If this is the
case, the question remains as to which component is the
initial target.
Furthermore, EPHB2-dependent and EPHB2-
independent effects of KLK8 blockade should be distin-
guished, in particular because KLK8 has additional
substrates besides EPHB2 with possible AD implications.
Our BLAST analysis of the KLK8 target recognition
sequence YGRY [3] identified eight-putative and one-
assured [2] KLK8 substrates. Two of these proteins, that is,
fibronectin and steroid 5 alpha-reductase 1 (Srd5a1), play a
role in AD and are therefore candidates for further testing
in the context of anti-KLK8 therapy. Cerebral fibronectin
levels are reduced already before AD onset in patients with
mild cognitive impairment [38]. Moreover, fibronectin pro-
motes the secretion of APP and impedes APP integration
into plasma membranes and subsequent Ab biogenesis
[39]. Accordingly, putative enhancement of fibronectin due
to KLK8 inhibition would offer an explanation of how anti-
KLK8 treatment inhibits amyloidogenic APP processing
and Ab generation. This explanation is of particular interest
because, based on KLK8 target recognition sequence [3],
neither APP processing secretases nor APP itself interacts
directly with KLK8. The other potential KLK8 substrate
candidate, Srd5a1 participates in the biosynthesis of allo-
pregnanolone which is a neurosteroid with anxiolytic proper-
ties [40]. AD patients have reduced allopregnanolone levels
[41], whereas allopregnanolone administration improves
cognitive performance and promotes hippocampal neurogen-
esis in the 3xTg AD mouse model [42,43]. Further
investigations should verify the effects of anti-KLK8 treat-
ment on fibronectin as well as Srd5a1-mediated allopregna-
nolone biosynthesis.
To exploit the therapeutic potential of anti-KLK8 treat-
ment, optimal antibody dose and treatment period must be
established. Our results indicate that KLK8 inhibition inter-
feres with early steps of the amyloid cascade, suggesting
possible prophylactic properties in the early disease stages.
Conversely, 4 weeks of antibody application was sufficient
to exert therapeutic effects in mice with moderate AD pa-
thology, hinting at potential curative benefits also in later
disease stages. Moreover, KLK8 should be evaluated as an
antecedent plasma and/or cerebrospinal fluid (CSF)
biomarker, as its cerebral expression is already increased
in preclinical stages of AD.
Ultimately, the most intriguing issue remains to verify the
bench-to-bedside translational potential of this novel thera-
peutic approach.Acknowledgments
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1. Systematic review: The clinical hallmarks of Alz-
heimer’s disease (AD) are memory loss and
increased anxiety. We hypothesized that the protease
kallikrein-8 (KLK8) is involved in the pathogenesis
of AD, as it is implicated in memory acquisition and
anxiety and its mRNA is elevated in AD-affected
human hippocampus.
2. Interpretation: The present study identifies KLK8 as a
possible antecedent biomarker of AD, as it was dras-
tically increased in both murine and human brain
before disease onset and qualifies this molecule as a
potential therapeutic target against AD, as antibody-
mediated KLK8 inhibition in an early disease stage
attenuatedmultiple AD-related behavioral, structural,
and molecular impairments in TgCRND8 mice.
3. Future directions: Future investigations should deter-
mine the optimal dose and treatment window for the
anti-KLK8 therapy, evaluate KLK8 as a CSF and/or
plasma biomarker and validate the bench-to-bedside
translational potential of anti-KLK8 therapy in AD
patients.
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